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Scientiﬁc meetingThe scientiﬁc meeting entitled ‘Anthelmintics: From Discovery to Resistance’ was held in San Francisco in
February 2014. The themes of the meeting were drug discovery, modes of action and resistance. Both
human and veterinary parasites were covered in the oral and poster presentations. The attendees were
from both academic and industrial backgrounds. In the present article we introduce a number of the
papers that emerged from the meeting. Several of the papers covered current drug discovery efforts
underway worldwide, with some speciﬁc examples focusing on ion channels, protein kinases and
cysteine proteases. These efforts included the repurposing of known drugs as well as the discovery of
novel actives. Two papers described recently-developed whole-organism screening techniques. Finally,
we introduce several papers looking at mechanisms and management of drug resistance in human and
veterinary parasites.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).In Memorium
Martin John Rogers 1960–2014
While we were preparing this Introduction, we were
shocked to hear of the death of John Rogers. John was a pro-
gram officer in Preclinical Drug Development at the National
Institute for Allergy and Infectious Diseases and interacted
with many of the US-based scientists at the meeting. His
two presentations on how NIH funding worked and what
were the best strategies for getting hold of some of it were
characteristically helpful, supportive and insightful. John
helped many of us over the years and his informed advice
and support will be much missed, both personally and pro-
fessionally. We dedicate this Special Issue to his memory.
This special issue of IJP-Drugs and Drug resistance contains a
number of papers that emerged from a scientiﬁc meeting entitled
‘Anthelmintics: From Discovery to Resistance’ that we organized
in San Francisco in February 2014. This followed on from a smallermeeting, concentrating on ion channels and anthelmintics, which
took place in Philadelphia in December 2011 (Wolstenholme,
2012). In putting together this latest meeting we were driven by
a desire to bring together as many groups as possible that were
working in this area, whether they were based in academic or
industrial settings, whether they concentrated on human or veter-
inary helminths, and whether those helminths were ‘round’ or
‘ﬂat’. We originally hoped that we could attract 70–80 people; in
the event we had to turn a very few late enquiries away as we were
nearing the capacity of the room and more than 130 registered,
which was extremely gratifying. Those who were there, heard a
total of 50 oral presentations over 3 days, and could look at 46
posters presented in two very lively and well-attended sessions.
The oral presentations were loosely arranged into three
‘themes’; discovery, modes of action and resistance, with a ﬁnal
session on funding issues and the way forward for the anthelmintic
research community. Though there is obviously some overlap
between the three areas, we have tried to arrange the contribu-
tions to this Special Issue in the same order. However, no-one
can do anything without resources and the presentations on fund-
ing were possibly the most important topic that was discussed. In
this issue, Ramamoorthi et al. (2014) describe The World Intellec-
tual Property Organization (WIPO) Re:Search consortium and how
it brings institutions, both academic and commercial, together to
form new collaborations, including those focused on anthelmintic
drug discovery. In less than three years, more than 90 institutions
have joined WIPO Re:Search, leading to over 70 research agree-
A.J. Wolstenholme, R.J. Martin / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 218–219 219ments between Consortium Members, of which 11 are focused on
anthelmintics.
Recently, there has been renewed interest in whole-organism
screening as part of the drug discovery process and Buckingham
et al. (2014) review recent progress in the automation of
measuring nematode behaviours, focusing on developments in
the application of machine vision, statistical imaging and tracking
approaches. Motility, in particular, offers a direct readout of
neuromuscular activity and the health of the animal and Storey
et al. (2014) describe a modiﬁcation of theWormAssay system ﬁrst
described by Marcellino et al. (2012) that permits assays to be
carried out on microscopic larval stages, such as microﬁlariae.
Identiﬁcation and validation of molecular targets remains cen-
tral to drug discovery efforts and several presentations discussed
established and new targets. The enormous success of themacrocy-
clic lactone anthelmintics has been a fantastic boon to parasite con-
trol and so it is ﬁtting that this issue contains discussion of their
targets, the glutamate-gated chloride channels (GluCls). Themacro-
cyclic lactones have no activity against trematodes and Lynagh et al.
(2014) provide a valuable comparisonof nematode and schistosome
GluCls, demonstrating that while the ﬂatworm channelsmay not be
affected by ivermectin, the ﬂatworm GluCls are potential as drug
targets in their own right. Protein kinases have been investigated
as targets for the development of drugs against many conditions,
and parasites are no exception. Morel et al. (2014) report studies
conﬁrming that inhibition of protein kinases has deleterious effects
on schistosomes, thereby highlighting protein kinase B (PKB or Akt)
as a novel target for anti-schistosome chemotherapy. Discovery of
the essential symbiotic relationship between Wolbachia and many
species of ﬁlarial nematode has opened up many new avenues for
research. Lustigman et al. (2014) report that nematode cysteine pro-
teases are required tomaintain this symbiosis and that inhibition of
their activity hinders microﬁlarial development and release, and
reduces Wolbachia DNA levels, suggesting that they have potential
as drug targets. Wolbachia themselves can be targeted by some
existing antibiotics, though these are not suitable for use in mass
drug administration programs. Johnston et al. (2014) report pro-
gress on drug development for onchocerciasis and lymphatic ﬁlari-
asis by repurposing of existing drugs, which already have regulatory
approval. However, Beckmann et al. (2014) provide a cautionary
tale of the problems that can be encountered during this process,
as the in vitro effects of Imatinib, a tyrosine kinase inhibitor, on adult
schistosomes could not be replicated in vivo. They report that the
blood constituents, serum albumin and alpha-1 acid glycoprotein,
inhibited the in vitro effects.
In parasitology, as in other infectious diseases, it is becoming
apparent that ‘resistance is inevitable’ and that we need to be
better at detecting the emergence of resistant helminths and
devising strategies to cope with them once they do appear.
Mwangi et al. (2014) report the apparent absence of schistosomes
with reduced sensitivity to praziquantel in Kenya, but they were
able to generate such parasites in the laboratory. They consider
that there is a possibility that praziquantel resistance could appear
if sufﬁcient selection pressure is applied. The mechanism of
such resistance is naturally of great interest and Greenberg
(2014) reviews one such possible mechanism, the schistosome
P-glycoproteins. The drug efﬂux transporters may not only
modulate sensitivity to praziquantel and other drugs, but they
have many other essential physiological roles, which we are only
beginning to understand. This might make them drug targets in
their own right. But if resistance does appear and become
established, what then? Matthews (2014) reviews strategies to
mitigate the effects of anthelmintic resistance, speciﬁcally inequine parasitic nematodes. She concludes that control of horse
nematodes must become less reliant on chemical anthelmintics
and make better use of management practices to reduce the
environmental impact of infections.
The success of a meeting like this depends on the help of many
people, in addition to the formal organizers. First, there is always a
need for money and we should like to thank the support we
received from Zoetis, New England Biolabs, Merial Ltd and the
Burroughs Wellcome Fund, and acknowledge the support received
via an R13 award from the NIAID (1R13AI109813-01). The views
expressed in this special issue do not necessarily reﬂect the ofﬁcial
policies of the Department of Health and Human Services; nor does
mention of trade names, commercial practices or organizations
imply endorsement by the US Government. Dr. James McKerrow,
Dr. Conor Caffrey, Dr. Judy Sakanari and their colleagues in San
Francisco were enormously helpful in many respects and made
our jobs much easier. We should also like to thank Jennifer Vit of
Iowa State University for handling the registration and ﬁnance so
efﬁciently and Dr. Barbara Reaves, Mary Maclean and Melissa
Miller for their help ‘on the ground’ in making sure things ran as
smoothly as possible.Conﬂict of interest
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